Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice - sprookjes - yvandenbroek - TriplyDB

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

http://www.wikidata.org/entity/Q35142813

about

The promise of immunotherapy in head and neck squamous cell carcinoma The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemot Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.Programmed death ligand 2 in cancer-induced immune suppression.Development of PROSTVAC immunotherapy in prostate cancer.Trial watch: Chemotherapy with immunogenic cell death inducers Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.Immunological off-target effects of standard treatments in gastrointestinal cancers Immunocombination therapy for high-risk neuroblastoma.The nature of activatory and tolerogenic dendritic cell-derived signal II.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?CAR T-cell immunotherapy: The path from the by-road to the freeway?Head and Neck Carcinoma Immunotherapy: Facts and Hopes.Immunotherapeutic Approaches to Biliary Cancer.PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity.Simultaneous assessment of NF-κB/p65 phosphorylation and nuclear localization using imaging flow cytometry Immunological effects of chemotherapy and radiotherapy against brain tumors.Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

P2860

Q26744433-78A8367C-D836-4266-ACAC-E7A475F12830 Q26766066-E704C81F-34AD-4B61-B758-E7891BB383D8 Q26776184-BBE6993C-F3BA-4906-BE2A-044853C1CB0F Q28069924-43BAD69C-B85D-47FF-8F06-9D24E93ABAE8 Q28076473-355BA11E-EE4B-4867-B6E7-5EF9B2B9789C Q28486600-27ACA7D2-9EAB-4CBC-88B3-7A24294EF541 Q34180369-F862CF1F-59AF-47CA-84F7-A5E7F3CCE838 Q34658452-E094D973-7B07-4171-BD39-A50AB43B87D9 Q35024484-49DA2749-EEAF-4C11-90F4-1D5CAE431745 Q35546869-2842A552-AD9E-4302-B7AC-7C5F6AC934CB Q35586871-69058CCC-D1D9-4ABE-9EB4-85F7D31735EA Q35837683-194469EE-CD1D-48FE-912B-D144A100A174 Q35955151-060FA8AF-67A5-45CB-95D3-E807AE3131D9 Q35981733-573090E1-DBD0-429B-A417-7F47FB2D70DC Q36038456-614C7EBC-24AD-46AA-BEB7-26175C2A8E93 Q36132761-17257FFC-3EE7-4A80-90FC-933DB2843A3B Q36224057-2CBB00DD-14B2-4799-9AE5-76262BC3E2A4 Q36903206-70A2BBBA-95DD-44B9-ACCC-1FB32521AF52 Q37142435-3FBFE8AC-00C6-4B55-B1FD-18E1B72608A9 Q37347999-C08F8613-E27D-4955-96EC-3DCDEB005FCD Q37373689-FBBA58A5-5A20-402C-B08E-46783DF12768 Q37404086-4C39D195-540D-429C-B523-AC951F47F640 Q37991024-27CC7902-A0ED-4EF9-B973-EED76673985D Q38085577-CF0C68D2-3180-453C-B701-E7C7742F5B36 Q38115968-49A167FE-8D6D-4A02-9A8A-601712B1644C Q38168953-5BC67AA8-023F-4928-8FD0-53B0C5CB2641 Q38174601-42B68EFF-067C-4578-A597-C2768E5A3C8F Q38248440-395D3785-D887-4292-97F1-27EDE5153708 Q38287054-48D62625-22DB-474A-A55A-CAACF72395F3 Q38447992-82CFB5FD-96AA-493E-B41C-266516F871CA Q38632105-B53AB8F6-E7C4-4CDB-92A3-D870BC6D9CD8 Q38650710-83AC2356-7FA7-461E-ABD2-59A13F4DCE73 Q38703148-246A7BBF-6D71-4B7E-B1C8-2379715C505F Q38817335-B6B03936-D17B-4BD8-A8BD-705EA5AC54D9 Q38888723-A0C5C5AB-8D9D-4F08-A68C-68F4BFC065DC Q38947116-1843C876-8055-4218-9BEC-B449CF384BE2 Q38984857-E080327E-8987-497C-A160-BA9B366C329F Q38993390-ECC1F635-0F1B-4DA1-B628-9D0907985789 Q39397337-ACB370EE-16F1-485E-A842-15579C6FD518 Q39646994-1EFD5585-F3B3-48BA-BE8C-2D2634CE71EF

P2860

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

http://www.wikidata.org/entity/Q35142813

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@ast

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@en

type

label

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@ast

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@en

prefLabel

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@ast

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@en

P1433

Q35142813-5333C9D7-82E2-4A6E-AE23-DE4C261855BF

P1476

Q35142813-7A98FB26-6882-45AE-A9F4-ED9F542216A1

P2093

Q35142813-2A01CE09-C444-45B3-A855-C5412CE220CF

Q35142813-31D0EBBA-92D9-41D4-BFB9-F01F3599D7D7

Q35142813-53A8A5DD-67FA-48BE-9C8C-52FB45421002

Q35142813-A63E2397-FBC4-42F3-9F8B-D8B6113E4867

Q35142813-B6129837-9AA8-4175-A6A6-496646E92617

Q35142813-BD841E0C-2AB4-4FC6-B70F-24462B298740

Q35142813-D1BF92D1-FE61-4AD3-A3F3-5368244629B8

Q35142813-D229BC6A-0435-4E74-9B1A-FA49F8DB7087

Q35142813-D407532B-AE15-4D4D-A0E8-29E20341B032

Q35142813-DDFF3235-E57C-4685-ABF1-2231B5F474FD

P2860

Q35142813-01465CE4-44C4-48B6-982A-7D6A618F8632

Q35142813-02868913-A4CD-4CA7-83BD-B2DDE2AB7F5B

Q35142813-0E78A8B4-06C8-4E11-95D5-B44C36F6BD5B

Q35142813-10BFFAE5-F18C-45D3-820A-B4FA7EE77F10

Q35142813-15342035-9D9A-4643-BF72-3789126D18E2

Q35142813-19C25650-D20D-4D52-AE71-467FF0C60532

Q35142813-2214269B-E302-4AB3-984C-39EBC304152E

Q35142813-284318B0-86F7-4C45-88E4-326B92006C02

Q35142813-460CC7E4-D63A-44BA-B416-95EA2207DC6E

Q35142813-47BB9D11-A41A-4090-94D1-EEFE2531CADD

P304

Q35142813-E4453E77-845C-4389-BB6E-509CC854A7BA

P31

Q35142813-82A67C79-95B1-4617-9502-16694F1D20C2

P356

Q35142813-5E8EA29F-A845-4AE5-A57A-201D54FBC80E

P407

Q35142813-BF4D63BA-A880-4B07-BB4A-5E36ECB49C67

P433

Q35142813-DE8678C3-D579-428B-804C-E489FCF7CB70

P478

Q35142813-1C3208AA-9C7E-4B99-A079-561C0D44234A

P50

Q35142813-5B5C8E78-BBDC-42D7-A7BF-1EFC38E3735D

Q35142813-858D8B8D-BB37-4195-8A98-150A8BA2B7E3

Q35142813-AB4EF34A-0837-4280-9F15-25A31B5D05EB

P577

Q35142813-FE338219-601F-4919-9ADC-AD8A3683FE37

P698

Q35142813-D338F0BC-4128-4A9C-B5AF-2EB7C4ABDF4B

P932

Q35142813-3922F1C3-3F2F-4576-B39E-D59A67C85950

P356

P1433

Journal of Clinical Investigation

P1476

Platinum-based drugs disrupt S ...... inst cancer in humans and mice

@en

P2093

Annemiek de Boer

http://www.w3.org/2001/XMLSchema#string

Bastiaan J H Jansen

http://www.w3.org/2001/XMLSchema#string

Carla M L Van Herpen

http://www.w3.org/2001/XMLSchema#string

Cornelis J A Punt

http://www.w3.org/2001/XMLSchema#string

Dagmar Eleveld-Trancikova

http://www.w3.org/2001/XMLSchema#string

Gosse J Adema

http://www.w3.org/2001/XMLSchema#string

I Jolanda M de Vries

http://www.w3.org/2001/XMLSchema#string

Johan H J M van Krieken

http://www.w3.org/2001/XMLSchema#string

Johannes H Kaanders

http://www.w3.org/2001/XMLSchema#string

Stanleyson V Hato

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

Calreticulin exposure dictates the immunogenicity of cancer cell death

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

P304

3100-3108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI43656

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Gerty Schreibelt

Stefan Nierkens

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21765211

http://www.w3.org/2001/XMLSchema#string

P932

3148725

http://www.w3.org/2001/XMLSchema#string